Physician profile
Arvind C Patel
NPI 1386662658
$9,997.88
in general payments reported to CMS, 2019-2025
26 companies · $94.49 in 2025
The $94.49 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $341 · 2020: $60.98 · 2021: $219 · 2022: $646 · 2023: $8,575 · 2024: $60.59 · 2025: $94.49.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $7,750 · Travel and Lodging: $676 · Food and Beverage: $305.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $7,750.00 |
| Travel and Lodging | $675.74 |
| Food and Beverage | $304.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $8,502.72 | 2023 | Davinci Xi, Da Vinci Surgical System |
| Merz North America, INC. | $612.78 | 2022 | |
| Janssen Pharmaceuticals, INC | $103.46 | 2019 | |
| Tela Bio, INC. | $94.49 | 2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Amneal Pharmaceuticals LLC | $81.05 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $71.36 | 2021-2022 | |
| Shire North American Group INC | $69.51 | 2019 | |
| Corcept Therapeutics | $53.91 | 2020-2021 | |
| Mannkind Corporation | $45.35 | 2019-2023 | Afrezza |
| Sanofi-Aventis U.S. LLC | $34.34 | 2023-2024 | |
| Innovation Technologies INC | $33.29 | 2023 | Irrisept |
| Abbott Laboratories | $31.67 | 2019-2020 | |
| Lilly USA, LLC | $29.84 | 2024 | Mounjaro, Zepbound |
| Valeritas, INC. | $26.79 | 2019 | |
| Novo Nordisk INC | $24.28 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.86 | 2021 | |
| Aroa Biosurgery Incorporated | $19.76 | 2022 | |
| Amarin Pharma, INC. | $18.64 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.23 | 2020 | |
| Medtronic, INC. | $18.20 | 2021 | |
| Indivior INC. | $16.75 | 2021 | |
| Horizon Therapeutics Plc | $16.00 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.10 | 2019 | |
| Amgen INC. | $13.97 | 2019 | |
| Ascensia Diabetes Care US INC. | $13.64 | 2024 | |
| Pear Therapeutics (US), INC. | $12.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arvind Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.